Nanotechnology: Future of oncotherapy

Clinical Cancer Research

Volumn 21, Issue 14, 2015, Pages 3121-3130

  Gharpure, Kshipra M ^a   Wu, Sherry Y ^a   Li, Chun ^a   Lopez Berestein, Gabriel ^a   Sood, Anil K ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALN VSP02; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ASPARAGINASE MACROGOL; CARBON NANOPARTICLE; CETUXIMAB; CREMOPHOR; DAUNORUBICIN; DECITABINE; DENDRIMER; DOXORUBICIN; GADOLINIUM CHELATE; GOLD NANOPARTICLE; IMMUNOLIPOSOME; LIPOSOME; LONTUCIREV; MACROGOL; NANOPARTICLE; ONCOLYTIC VIRUS; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEXASTIMOGENE DEVACIREPVEC; POLYGLACTIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SMALL INTERFERING RNA; TKM 080301; TRASTUZUMAB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TUMOR MICROENVIRONMENT; X RAY; ANIMAL; NEOPLASMS; ONCOLOGY; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MEDICAL ONCOLOGY; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS;

EID: 84942914138     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1189     Document Type: Review

References (114)

1. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics, and imaging. Nanomedicine 2012;8:147-66.
2. Swenson CE, Bolcsak LE, Batist G, Guthrie TH Jr, Tkaczuk KH, Boxenbaum H, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003;14:239-46.
3. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995;13:996-1003.
4. Batist G, RamakrishnanG, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-54.
5. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
6. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment ofmetastatic breast cancer. Ann Oncol 2004;15:440-9.
7. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;4:15-21.
8. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane (+) ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009;4:99-105.
9. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, proteinstabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44.
10. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
11. Li C, Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 2008;60:886-98.
12. Li C, Yu DF, Newman RA, Cabral F, Stephens LC, Hunter N, et al. Complete regression of well-established tumors using a novel watersoluble poly (L-glutamic acid)-paclitaxel conjugate. Cancer Res 1998;58:2404-9.
13. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, et al. Preclinical development and clinical translation of a PSMAtargeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012;4:128ra39.
14. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther 2006;5:2957-62.
15. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81.
16. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, et al. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials 2011;32:8548-54.
17. Zheng Y, Yu B, Weecharangsan W, Piao L, Darby M, Mao Y, et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int J Pharm 2010;390:234-41.
18. Hamaguchi T, Matsumura Y, Nakanishi Y, Muro K, Yamada Y, Shimada Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci 2004;95:608-13.
19. Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol 2012;262:1-10.
20. Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFRimmunoliposomes in advanced solid tumours: a phase 1 doseescalation study. Lancet Oncol 2012;13:1234-41.
21. Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M, et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 2013;21:1096-103.
22. Jin C, Yang Z, Yang J, Li H, He Y, An J, et al. Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: a targeted therapy for liver cancer stem cells. J Nanopart Res 2013;16:1-15.
23. Li SY, Sun R, Wang HX, Shen S, Liu Y, Du XJ, et al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J Control Release 2014;15:00748-2.
24. Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16:3910-22.
25. Amstad E, Kohlbrecher J, Muller E, Schweizer T, Textor M, Reimhult E. Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containingmembranes. Nano Lett 2011;11:1664-70.
26. Derfus AM, vonMaltzahn G, Harris TJ, Duza T, Vecchio KS, Ruoslahti E, et al. Remotely triggered release from magnetic nanoparticles. Adv Mater 2007;19:3932-6.
27. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, Bur M, et al. Pulsedhigh intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007;13:2722-7.
28. Fomina N, McFearin C, Sermsakdi M, Edigin O, Almutairi A. UV and near-IR triggered release from polymeric nanoparticles. J Am Chem Soc 2010;132:9540-2.
29. Giri S, Trewyn BG, Stellmaker MP, Lin V S Y. Stimuli-responsive controlledrelease delivery system based on mesoporous silica nanorods cappedwith magnetic nanoparticles. Angew Chem Int Ed 2005;44:5038-44.
30. Farooqi AA, Rehman Zu, Muntane J. Antisense therapeutics in oncology: current status. OncoTargets Ther 2014;7:2035-42.
31. Schreier H, Gagne L, Bock T, Erdos GW, Druzgala P, Conary JT, et al. Physicochemical properties and in vitro toxicity of cationic liposome cDNA complexes. Pharm Acta Helv 1997;72:215-23.
32. Guo S, Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J Nanomaterials 2011;2011:12.
33. Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1997;1329:345-56.
34. Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, Keil O, et al. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol 2014;32:4141-8.
35. Aleku M, Schulz P, Keil O, Santel A, SchaeperU, Dieckhoff B, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008;68:9788-98.
36. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-man trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013;3:406-17.
37. Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging the undruggable. Sci Transl Med 2014;6:240ps7.
38. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-8.
39. Zhao W, Zhuang S, Qi XR. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine 2011;6:3087-98.
40. Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotech 2013;31:638-46.
41. Wong SC, Klein JJ, HamiltonHL, Chu Q, Frey CL, Trubetskoy VS, et al. Coinjection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther 2012;22:380-90.
42. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008;60:1307-15.
43. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR, Gannon WE, Walker M, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010;16:6139-49.
44. Shimizu T, Kishida T, Hasegawa U, Ueda Y, Imanishi J, Yamagishi H, et al. Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy. Biochem Biophys Res Commun 2008;367:330-5.
45. Yao H, Ng SS, Huo LF, Chow BK, Shen Z, Yang M, et al. Effective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticle. Mol Cancer Ther 2011;10:1082-92.
46. Mansour M, Pohajdak B, Kast WM, Fuentes-Ortega A, Korets-Smith E, Weir GM, et al. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J Transl Med 2007;5:20.
47. Wang C, Zhuang Y, Zhang Y, Luo Z, Gao N, Li P, et al. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 2012;30:4790-9.
48. Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 2011;32:3666-78.
49. Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release 2002;85:247-62.
50. Yan W, Chen W, Huang L. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release 2008;130:22-8.
51. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006;117:78-88.
52. Mukai Y, Yoshinaga T, Yoshikawa M, Matsuo K, Yoshikawa T, Niki K, et al. Induction of endoplasmic reticulum-endosome fusion for antigen crosspresentation induced by poly (gamma-glutamic acid) nanoparticles. J Immunol 2011;187:6249-55.
53. Nakamura T, Moriguchi R, Kogure K, Shastri N, Harashima H. Efficient MHCclass I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. Mol Ther 2008;16:1507-14.
54. Yuba E, Kojima C, Harada A, Tana, Watarai S, Kono K. pH-Sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Biomaterials 2010;31:943-51.
55. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008;354:56-62.
56. Pham CT, Mitchell LM, Huang JL, Lubniewski CM, Schall OF, Killgore JK, et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem 2011;286:123-30.
57. Jing-Liang L, Gu M. Gold-nanoparticle-enhanced cancer photothermal therapy. IEEE J Sel Top Quantum Electron 2010;16:989-96.
58. Huff TB, Tong L, Zhao Y, Hansen MN, Cheng JX, Wei A. Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine 2007;2:125-32.
59. Yuan A, Wu J, Tang X, Zhao L, Xu F, Hu Y. Application of near-infrared dyes for tumor imaging, photothermal, and photodynamic therapies. J Pharm Sci 2013;102:6-28.
60. Peng CL, Shih YH, Lee PC, Hsieh TM, Luo TY, Shieh MJ. Multimodal image-guided photothermal therapymediated by 188Re-labeledmicelles containing a cyanine-type photosensitizer. ACS Nano 2011;5:5594-607.
61. Yu J, Javier D, Yaseen MA, Nitin N, Richards-Kortum R, Anvari B, et al. Self-assembly synthesis, tumor cell targeting, and photothermal capabilities of antibody-coated indocyanine green nanocapsules. J Am Chem Soc 2010;132:1929-38.
62. Zheng X, Xing D, Zhou F, Wu B, ChenWR. Indocyanine green-containing nanostructure as near infrared dual-functional targeting probes for optical imaging and photothermal therapy. Mol Pharm 2011;8:447-56.
63. Huang X, El-Sayed MA. Gold nanoparticles: optical properties and implementations in cancer diagnosis and photothermal therapy. J Adv Res 2010;1:13-28.
64. Shao J, Griffin RJ, Galanzha EI, Kim J-W, Koonce N, Webber J, et al. Photothermal nanodrugs: potential of TNF-gold nanospheres for cancer theranostics. Sci Rep 2013;3:1293.
65. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A 2003;100:13549-54.
66. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photo-thermal tumor ablation inmice using near infrared-absorbing nanoparticles. Cancer Lett 2004;209:171-6.
67. El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett 2006;239:129-35.
68. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 2006;128:2115-20.
69. You J, Zhang R, Zhang G, Zhong M, Liu Y, Van Pelt CS, et al. Photothermalchemotherapy with doxorubicin-loaded hollow gold nanospheres: a platform for near-infrared light-trigged drug release. J Control Release 2012;158:319-28.
70. You J, Zhou J, Zhou M, Liu Y, Robertson J, Liang D, et al. Pharmacokinetics, clearance, and biosafety of polyethylene glycol-coated hollow gold nanospheres. Part Fibre Toxicol 2014;11:26.
71. Zhou M, Zhang R, Huang M, Lu W, Song S, Melancon MP, et al. A chelatorfree multifunctional [64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy. J Am Chem Soc 2010;132:15351-8.
72. Li Y, Lu W, Huang Q, Huang M, Li C, Chen W. Copper sulfide nanoparticles for photothermal ablation of tumor cells. Nanomedicine 2010;5:1161-71.
73. ∗ magnetic resonance imaging. Invest Radiol 2011;46:132-40.
74. Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res 2010;12:2313-33.
75. Murphy CJ, Gole AM, Stone JW, Sisco PN, Alkilany AM, Goldsmith EC, et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res 2008;41:1721-30.
76. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005;26:3995-4021.
77. Pisanic Ii TR, Blackwell JD, Shubayev VI, Fiñones RR, Jin S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 2007;28:2572-81.
78. Harisinghani MG, Barentsz J, Hahn PF, DesernoWM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9.
79. Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging 2009;33:301-5.
80. Neuwelt EA, Varallyay P, Bago AG, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol 2004;30:456-71.
81. Kobayashi H, Kawamoto S, Sakai Y, Choyke PL, Star RA, Brechbiel MW, et al. Lymphatic drainage imaging of breast cancer in mice by micromagnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst 2004;96:703-8.
82. Jain S, Hirst DG, O'Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Brit J Radiol 2012;85:101-13.
83. Popovtzer R, Agrawal A, Kotov NA, Popovtzer A, Balter J, Carey TE, et al. Targeted gold nanoparticles enable molecularCT imaging of cancer. Nano Lett 2008;8:4593-6.
84. Wang Z. Plasmon-resonant gold nanoparticles for cancer optical imaging. Sci China Phys, Mech Astron 2013;56:506-13.
85. Liu Y, Chen Z, Liu C, Yu D, Lu Z, Zhang N. Gadolinium-loaded polymeric nanoparticles modified with anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer. Biomaterials 2011;32:5167-76.
86. Zhang HW, Wang LQ, Xiang QF, Zhong Q, Chen LM, Xu CX, et al. Specific lipase-responsive polymer-coated gadolinium nanoparticles for MR imaging of early acute pancreatitis. Biomaterials 2014;35:356-67.
87. Manus LM, Mastarone DJ, Waters EA, Zhang X-Q, Schultz-Sikma EA, MacRenaris KW, et al. Gd (III)-nanodiamond conjugates for MRI contrast enhancement. Nano Lett 2009;10:484-9.
88. Reul R, Tsapis N, Hillaireau H, Sancey L, Mura S, Recher M, et al. Near infrared labeling of PLGA for in vivo imaging of nanoparticles. Polym Chem 2012;3:694-702.
89. Magrez A, Kasas S, Salicio V, Pasquier N, Seo JW, Celio M, et al. Cellular toxicity of carbon-based nanomaterials. Nano Lett 2006;6:1121-5.
90. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013;19:329-36.
91. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005;12:437-45.
92. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014;14:559-67.
93. Gao W, Xiang B, Meng TT, Liu F, Qi XR. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironmentsensitive polypeptides. Biomaterials 2013;34:4137-49.
94. Soppimath KS, Liu LH, Seow WY, Liu SQ, Powell R, Chan P, et al. Multifunctional core/shell nanoparticles self-assembled from pHinduced thermosensitive polymers for targeted intracellular anticancer drug delivery. Adv Funct Mater 2007;17:355-62.
95. Xiao D, Jia H-Z, Zhang J, Liu C-W, Zhuo R-X, Zhang X-Z. A dual-responsive mesoporous silica nanoparticle for tumor-triggered targeting drug delivery. Small 2014;10:591-8.
96. Huang S, Shao K, Liu Y, Kuang Y, Li J, An S, et al. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 2013;7:2860-71.
97. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012;338:903-10.
98. Theek B, Rizzo LY, Ehling J, Kiessling F, Lammers T. The theranostic path to personalized nanomedicine. Clin Transl Imaging 2014;2:66-76.
99. Theek B, Gremse F, Kunjachan S, Fokong S, Pola R, Pechar M, et al. Characterizing EPR-mediated passive drug targeting using contrastenhanced functional ultrasound imaging. J Control Release 2014;182:83-9.
100. Sawant RR, Jhaveri AM, Koshkaryev A, Qureshi F, Torchilin VP. The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy. J Drug Target 2013;21:630-8.
101. Goodman TT, Ng CP, Pun SH. 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. Bioconjug Chem 2008;19:1951-9.
102. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011;11:135-41.
103. Bartlett D, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 2013;12:103.
104. Al-Ghananeem AM, Malkawi AH, Muammer YM, Balko JM, Black EP, Mourad W, et al. Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS PharmSci-Tech 2009;10:410-7.
105. Chattopadhyay N, Fonge H, Cai Z, Scollard D, Lechtman E, Done SJ, et al. Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol Pharm 2012;9:2168-79.
106. Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 2004;112:335-40.
107. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001;74:317-23.
108. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006;103:6315-20.
109. Jabbour M, Massad C, Boulos F. Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma. Breast Cancer Res Treat 2012;135:29-37.
110. Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 2013;59:252-60.
111. Xu Q, Liu Y, Su S, Li W, Chen C, Wu Y. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 2012;33:1627-39.
112. Ko HY, Choi KJ, Lee CH, Kim S. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin alphavbeta3 and tenascin-C proteins. Biomaterials 2011;32:1130-8.
113. Kluza E, van der Schaft D W J, Hautvast P A I, Mulder W J M, Mayo KH, Griffioen AW, et al. Synergistic targeting of avb3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combinedMR imaging and treatment of angiogenesis. Nano Lett 2010;10:52-8.
114. Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006;114:277-87.